Trial Profile
A Phase 1b/2 Study of the Oral CDK4/6 Inhibitor LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in Metastatic Castration Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 Sep 2022
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Prednisone (Primary) ; Ribociclib (Primary) ; Filgrastim
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Feb 2022 Results published in the Clinical Cancer Research
- 26 Oct 2021 Status changed from active, no longer recruiting to completed.
- 08 Jun 2021 Primary endpoint of radiographic progression-free survival rate has been met, according to results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.